EGFR and lung carcinoma: To study whether HDACi MS‐275 and gefitinib had a synergistic effect on EGFR‐TKI resistant lung cancer cells, we first tested the cell toxicity of MS‐275 or in combination with gefitinib in various lung cancer cells harboring different EGFR mutations shown in Figure 2A–C.